Rocket Pharmaceuticals Files 8-K for Operations Update
Ticker: RCKTW · Form: 8-K · Filed: May 6, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Rocket Pharma filed an 8-K, expect more details soon.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signals a routine update on the company's financial status and operational results, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- 0001140361-24-024574 (filing_id) — Accession Number
- May 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36829 (company_id) — SEC File Number
- 9 Cedarbrook Drive, Cranbury, NJ 08512 (address) — Principal Executive Offices
- 646-440-9100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or operational updates are being reported in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific results or updates within this excerpt.
When was this 8-K filing submitted to the SEC?
The filing was submitted on May 6, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
What is Rocket Pharmaceuticals, Inc.'s SEC File Number?
Rocket Pharmaceuticals, Inc.'s SEC File Number is 001-36829.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-05-06 17:26:57
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20028575_8k.htm (8-K) — 30KB
- ef20028575_ex99-1.htm (EX-99.1) — 82KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-24-024574.txt ( ) — 262KB
- rckt-20240506.xsd (EX-101.SCH) — 4KB
- rckt-20240506_lab.xml (EX-101.LAB) — 21KB
- rckt-20240506_pre.xml (EX-101.PRE) — 16KB
- ef20028575_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On May 6, 2024, Rocket Pharmaceuticals, Inc. (the "Company") announced certain preliminary financial information for the quarter ended March 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated May 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: May 6, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP